- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Calidi BioTherapeutics GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
| Do | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | 158 | GlobeNewswire (Europe) | Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end... ► Artikel lesen | |
| 08.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com | ||
| 20.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Calidi to present RedTail platform data at Iceland conference | 2 | Investing.com | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Calidi BioTherapeutics GAAP EPS of -$5.95 | 2 | Seeking Alpha | ||
| 27.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | 178 | GlobeNewswire (Europe) | Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its... ► Artikel lesen | |
| 24.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials | 1 | GlobeNewswire (USA) | ||
| 12.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing | 1 | GlobeNewswire (USA) | ||
| 10.03. | Calidi Biotherapeutics closes $6M public offering | 1 | Investing.com | ||
| 10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 1 | GlobeNewswire (USA) | ||
| 06.03. | Calidi BioTherapeutics prices $5.2M underwritten public offering | 1 | Seeking Alpha | ||
| 06.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering | 2 | GlobeNewswire (USA) | ||
| 06.03. | Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours - Here's Why | 1 | Benzinga.com | ||
| 06.03. | Calidi Biotherapeutics announces underwritten public offering | 1 | Investing.com | ||
| 06.03. | Calidi BioTherapeutics plans public offering of stock, pre-funded warrants; shares down | 1 | Seeking Alpha |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | Community Rückblick: wO-User zu BioNTech Quartalsbericht: "Oh wow, die Zahlen sind eine Katastrophe!" | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech steht nach neuen Quartalszahlen und angekündigten Standortschließungen weiter unter Druck. Hohe Verluste, Umbau des Geschäfts und das Aus... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,017 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,100 | +2,69 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026... ► Artikel lesen | |
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,177 Euro und damit -1,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.